# Ada Health Financial Model AI-powered symptom assessment app and clinical decision-support platform for consumers and healthcare partners. - Canonical: https://finamodel.com/startups/ada-health - Excel download: https://finamodel.com/startup-models/ada-health.xlsx - Category: Biotech/Pharma - Model type: SaaS ARR / Valuation - Funding round: Series B - Funding: $90M - Founded: 2021 - Geography: Global; partnerships in UK (NHS), US (Sutter Health), France (SANTÉCLAIR), Germany (Labor Berlin), Saudi Arabia (Obékan), and multinational pharma (Pfizer, Takeda). - Customer: B2B2C ## About the company Ada Health is a conversational AI symptom-assessment and care-navigation platform for consumers and healthcare partners. It combines diagnostic questioning, connection to healthcare professionals, and symptom or condition tracking in a personal health profile, and is available in ten languages after more than nine years of R&D. The consumer app is free to download, while the research implies enterprise licensing, API, or white-label fees from health systems, insurers, and pharma partners. Sutter Health, SANTÉCLAIR, Pfizer, Takeda, Labor Berlin, Samsung, Botnar, and Obékan are listed partners, although pricing and contract values are undisclosed. Ada reports more than ten million users, 20 million assessments, a 4.7 app rating, and 270,000-plus in-app ratings. An NHS pilot found 97% of users found it easy to use. The model should separate consumer engagement from partner contracts, per-assessment or subscription revenue, clinical validation, and retention. ## What's included - 5-year monthly revenue build with stage-appropriate growth assumptions - Full P&L, headcount plan, and operating-expense schedule - Cash-flow statement, runway, and burn-rate tracking - Valuation via exit multiple with a DCF cross-check - Returns analysis with MOIC and IRR - Unit economics including CAC, LTV, payback, and cohort retention ## Product & value proposition - Conversational, AI-driven symptom assessment app ("Ada") using diagnostic reasoning to triage users and navigate them to appropriate care. - Three core pillars: (1) diagnostic information via conversational interface; (2) access - direct connection to healthcare professionals; (3) management - symptom/condition tracking and personal health profile. - Available in 10 languages; tests thousands of diseases and symptoms to a "gold standard". - 9+ years of R&D; 230 employees, ~50 medical experts. - Positioning: highest diagnostic accuracy, advice safety on par with GPs, and highest consumer satisfaction among symptom-assessment apps. ## Revenue model Not explicitly stated in deck. The following can be inferred from the partner list and product positioning: - B2B enterprise licensing: health systems, insurers, and pharma partners (Sutter Health, SANTÉCLAIR, Pfizer, Takeda, Labor Berlin, Samsung, Botnar, Obékan) likely pay API/white-label access fees or per-assessment fees to embed Ada's clinical AI. Rationale: deck emphasises "adaptable and scalable, provider agnostic" and "trusted partner for clinical AI". - Consumer app revenue: freemium model with potential premium subscription or upsell to teleconsultation. Rationale: app is free to download (cited as "most popular"); monetisation route not stated. - No pricing, contract sizes, or revenue figures disclosed in deck. ## Traction & metrics - 10M+ users - 20M+ assessments completed - Available in 10 languages - 230 employees, ~50 medical experts - 4.7 / 5.0 average app rating - 270,000+ in-app ratings - 266,000 five-star reviews vs. Comp. 1: 26k, Comp. 2: 61k, Comp. 3: 11k, Comp. 4: 10k - approximately 8x nearest competitor - Partners: Sutter Health, SANTÉCLAIR, Pfizer, Takeda, Labor Berlin, Samsung, Botnar, Obékan - NHS pilot (500+ patients, 20 doctors): 97% found Ada easy to use; 86% would use again; 15% would not have attended clinic had they used Ada first - Care navigation metric: ">20%" ER use reduction indicated on chart - No revenue, ARR, GMV, or growth-rate figures disclosed. ## Competition / moat - Competitors named implicitly (Babylon cited by name in expert quote; four unnamed competitors shown in 5-star review chart). - Moat claims: - Clinical accuracy: 71% diagnostic accuracy vs. 38% competitor average (Gilbert et al., 2020, BMJ Open). - Condition coverage: 99% - highest among competitors. - Advice safety: 97% - on par with GPs vs. 90% competitor average. - 9+ years of proprietary R&D and 20M+ assessment data flywheel. - ~50 in-house medical experts - structural clinical investment competitors lack. - Network of enterprise partners creates integration depth and switching costs. ## Team & funding ask / use of funds - Co-founder & CEO: Daniel Nathrath - 20+ years experience; prior: BCG, viagogo, LYCOS. - Co-founder & Chief Science Officer: Dr. Martin Hirsch, PhD - 25+ years experience. - Co-founder & Chief Medical Officer: Dr. Claire Novorol, MD, PhD - 15+ years experience; NHS background. - CTO: Urban Liebel, PhD - 25+ years experience; KIT background. --- ## Recommended financial model - **Archetype + why:** B2B SaaS / enterprise health-tech revenue model with a consumer volume overlay. Ada's primary value accrues through enterprise licensing deals (health systems, pharma, insurers), which are SaaS-like in structure (annual contracts, API seat/usage fees). A secondary consumer engagement layer (free app + potential premium) drives user scale, which in turn strengthens the enterprise data and sales proposition. Model should be a dual-stream SaaS + consumer P&L feeding into a unified 3-statement forecast. - **Forecast horizon & granularity:** 5-year annual (2021–2025), with Year 1 broken into quarterly columns for cash planning given no revenue figures are disclosed and ramp dynamics matter. - **Key drivers & assumptions:** *Enterprise (B2B) stream:* - Number of enterprise partners (contracts): 8 named as of May 2021; grow at 6–10 new logos/year - rationale: early-stage pipeline, large addressable partner universe. - Average contract value (ACV): $200k–$500k/year per enterprise partner - rationale: health-system API integrations typically in this range; no deck data. - Contract expansion / upsell rate: 15% NRR uplift - rationale: usage-based component (per-assessment) likely scales with patient volume. - Enterprise gross margin: 70–75% - rationale: software delivery with clinical ops overhead; no deck data. *Consumer (B2C) stream:* - Monthly active users: derived from 10M+ total users; assume 15–20% MAU/install ratio = ~1.5–2M MAU. - Consumer ARPU: $0–2/user/year - rationale: primarily free app; minimal monetisation disclosed; may be zero in near term. - Consumer gross margin: 80%+ (pure software). *Opex:* - Headcount: 230 employees; average fully-loaded cost €120k/employee - rationale: Berlin HQ, mix of medical, tech, commercial. - R&D as % of revenue: 35–45% in early years, declining toward 25% at scale. - Sales & marketing: 20–30% of revenue - B2B enterprise sales motion, enterprise sales cycles are long. - G&A: 10–15% of revenue. *Clinical differentiation (model input, not driver):* - Diagnostic accuracy: 71%; condition coverage: 99%; advice safety: 97% - used as qualitative moat support, not a financial driver per se. - **Scenarios (Base / Bull / Bear - which variables flex):** - **Base:** 8→18 enterprise logos over 5 years; ACV $250k; consumer ARPU $1; headcount grows 15%/year. - **Bull:** Accelerated partnership wins (pharma real-world evidence use case drives faster closes), ACV expansion to $400k+, consumer premium tier launches. - **Bear:** Enterprise sales cycles longer than modelled (12–18 months to close), ACV compression on smaller health-system deals, consumer remains entirely free. - **Required sheets / outputs:** 1. Assumptions - all drivers in one place, tagged DECK vs. ASSUMED. 2. Enterprise Revenue - logo count × ACV × retention/expansion. 3. Consumer Revenue - MAU × ARPU. 4. P&L (Income Statement) - revenue, gross profit, operating expense lines, EBITDA. 5. Headcount Plan - by function (R&D, Medical, Commercial, G&A). 6. Cash Flow & Runway - given no funding ask is shown, model should show implied cash burn and months of runway at various raise sizes. 7. KPI Dashboard - MAU, enterprise logos, ACV, NRR, gross margin %, EBITDA margin %. ## Frequently asked questions ### Is the Ada Health financial model free? Yes. The Ada Health model is a free Excel download with live formulas. ### Can I change the assumptions? Yes. The workbook is editable and its live formulas recalculate when assumptions change.